Division of Infectious Disease, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
J Clin Virol. 2010 Apr;47(4):325-9. doi: 10.1016/j.jcv.2010.01.003. Epub 2010 Feb 24.
The occurrence of herpes zoster can deteriorate the quality of life considerably, resulting in high disease burden. While Korea is assumed to have high disease burden of herpes zoster, there has been no researches analyzing this.
We performed this study to investigate the disease burden of herpes zoster in the Korean population as a whole.
We used the database of the Health Insurance Review & Assessment Service of Korea and analyzed the data of patients who had herpes zoster as a principal diagnosis during the period from 2003 to 2007. We investigated the annual prevalence, rate of clinical visits, rate of hospitalization, and the pattern of medical services use. The socioeconomic burden of herpes zoster was calculated by a conversion into cost.
Rates of clinic visits and hospitalizations due to herpes zoster during the 5-year period from 2003 to 2007 were 7.93-12.54 per 1000 population and 0.22-0.32 per 1000 population, respectively. Prevalence rates according to age increased sharply after 50 years and reached a peak at 70 years. The total socioeconomic cost of herpes zoster was $75.9-143.8 million per year, increasing every year by 14-20%.
There is a heavy socioeconomic burden due to herpes zoster in Korea and indicate that appropriate policies need to be established to reduce this burden. Additional researches are also necessary to assess the safety, efficacy and cost-effectiveness of a herpes zoster vaccine in the Korean population.
带状疱疹的发生会极大地降低生活质量,导致疾病负担沉重。虽然韩国被认为带状疱疹疾病负担高,但尚未有分析这一问题的研究。
我们进行这项研究旨在调查韩国人群带状疱疹的疾病负担。
我们使用韩国健康保险审查与评估服务数据库,分析了 2003 年至 2007 年期间以带状疱疹为主要诊断的患者数据。我们调查了年度患病率、临床就诊率、住院率以及医疗服务使用模式。带状疱疹的社会经济学负担通过转化为成本来计算。
2003 年至 2007 年 5 年间,因带状疱疹就诊和住院的比例分别为每 1000 人 7.93-12.54 次和每 1000 人 0.22-0.32 次。年龄相关的患病率在 50 岁后急剧上升,在 70 岁时达到峰值。带状疱疹的总社会经济学成本每年为 7590 万至 1.438 亿美元,每年增长 14-20%。
韩国带状疱疹的社会经济学负担沉重,表明需要制定适当的政策来减轻这一负担。还需要进行更多的研究来评估带状疱疹疫苗在韩国人群中的安全性、疗效和成本效益。